Oncology Search
Oncology Oncology
prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Introduction

  • One of the most common cancers in men >50 years of age 

Signs and Symptoms

  • Weak urinary stream
  • Polyuria, nocturia
  • Hematuria
  • Erectile dysfunction
  • Pelvic pain, back pain, chest pain
  • Lower extremity weakness or numbness
  • Loss of bladder or bowel control

Risk Factors

  • Age (increased risk in men >50 years old)
  • Positive family history (1st-degree relatives and relatives diagnosed with prostate cancer at an early age doubles the risk)
  • Ethnicity (African-American, Caribbean men of African ancestry)
  • Chemical exposures (toxic combustion products)
  • Genetic mutations: Breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2) mutations, deoxyribonucleic acid (DNA) mismatch repair genes [MutS Homolog 2 (MSH2), MutL Homolog 1 (MLH1), Lynch syndrome], insulin-like growth factor-1 (IGF-1)
  • Other risk factors under research include a positive medical history of inflammation of the prostate gland [eg prostatitis, STDs, proliferative inflammatory atrophy (PIN)] and vasectomy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
A report of the first patient in Malaysia who had successfully completed 16 cycles of brentuximab vedotin
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
Hodgkin's lymphoma patients experience fatigue even after treatment
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Measurable residual disease in AML: Reduced-intensity conditioning associated with poorer post-transplant outcomes
Natalia Reoutova, 16 Jul 2019
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.